GATC Health’s Groundbreaking Stem Cell Therapy Could Revolutionize Diabetes Care

Novel approach designed to offer a more personalized and effective treatment option for patients suffering from diabetes and potentially other diseases.

Irvine, CA, February 4, 2025 — GATC Health Corp., a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, announces significant progress in its research to develop a more effective treatment for diabetes. In a comprehensive review article recently published in the American Journal of Biomedical Science & Research, GATC’s team detail a novel approach using a patient’s own stem cells to potentially address both Type 1 and Type 2 diabetes, as well as the potential for autologous stem cells to be expanded and differentiated into other cell types for diseases including Parkinson, Alzheimers, and others.

The paper, “Islet Transplantation using one’s own differentiated stem cells: A Review and Potential Applications,” discusses this innovative therapy, known as autologous bone marrow-derived mononuclear cell (BMMNC) infusion, offers new hope for the millions of people worldwide living with diabetes. Diabetes, a chronic disease affecting over 537 million adults globally, has long been a challenge for medical professionals to manage effectively.

The treatment involves collecting stem cells from the patient's own bone marrow, processing them, and then reintroducing them into the body. This autologous approach minimizes the risk of immune rejection, making it a safer option compared to other cell transplantation methods. Patient selection and monitoring will be optimized using GATC Health’s AI platform, Multiomics Advanced Technology™ (MAT). MAT will ensure selection of the best candidates for transplantation and will help monitor and manage post-treatment care for patients. 

Traditional treatments, such as insulin injections and dietary control, often fall short in providing long-term disease management of Type 2 diabetes. However, this new stem cell approach is demonstrating impressive results in clinical trials. Key findings from the review include: 

1. Safety and Effectiveness: Autologous infusion of stem cells in initial clinical trials has proven to be both safe and effective, with the potential for widespread application in diabetic patients

2. Improved Blood Sugar Control: Patients receiving this therapy showed significant improvements in blood sugar levels, insulin production, and overall glycemic control

3. Reduced Medication Dependence: Many patients were able to decrease their reliance on insulin and other diabetes medications following the treatment

4. Long-lasting Effects: Some studies reported sustained benefits for up to 36 months after the stem cell infusion

5. Versatile Application: The therapy shows promise for both Type 1 and Type 2 diabetes, as well as diabetes-related complications

The lead author of the review, Dr. Jonathan RT Lakey, PhD, MSM, Professor Emeritus UC Irvine and Chair of the Scientific Advisory Board of GATC Heath, stated, “This innovative therapy represents a significant leap forward in diabetes treatment. By harnessing the regenerative power of a patient’s own stem cells, we’re opening new doors for long-term disease management and potentially improved quality of life for millions of diabetes sufferers.” 

These initial results are highly encouraging, and additional research will help researchers fully understand the long-term effects and optimize the treatment protocol. As this therapy continues to develop, it could revolutionize diabetes care, offering a more personalized and effective treatment option for patients worldwide. The review emphasizes the need for continued research and clinical trials to further refine this promising approach. As GATC Health continues to explore the potential of stem cell therapy, people living with diabetes may soon have access to a powerful new tool in their fight against this chronic disease.

Download the paper here.

About GATC Health Corp

GATC Health Corp is a technology company revolutionizing drug discovery and development through its transformative AI platform and approach. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) simulates human biochemistry’s billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and de-risk drug pipelines by predicting efficacy, safety, and off-target effects. For more information, visit www.gatchealth.com.